Navigation Links
Theravent, Inc. exceeds 4.5 million nights of sleep apnea and snoring treatment

SAN JOSE, Calif., Oct. 29, 2013 /PRNewswire/ -- Theravent, Inc., a medical device company providing noninvasive solutions for people with sleep disordered breathing, recently hit a milestone when their Provent® Sleep Apnea Therapy and Theravent™ Advanced Nightly Snore Therapy products exceeded 4.5 million nights of treatment, collectively. Both products feature Expiratory Positive Airway Pressure (EPAP) therapy to treat Obstructive Sleep Apnea (OSA) and snoring.

Clinically proven by leading sleep specialists to treat both snoring and OSA, EPAP therapy represents a breakthrough in the battle against sleep related breathing disorders. It features MicroValve technology, which attaches and covers the nostrils to create pressure during exhalation. EPAP keeps a person's airway open while they sleep and prevents sleep disordered breathing and snoring.

Since 2009, over four million nights of Provent have been prescribed to treat OSA patients, while more than 400,000 nights of Theravent have been used over the past year to stop snoring and achieve a quieter night's sleep.

"We're pleased to see these therapies helping people around the world by treating conditions that have been linked to serious health problems, such as high blood pressure, stroke and heart attack," said Theravent, Inc. CEO Matt Williams. "In addition, these treatments provide quieter nights for bed partners, who are often negatively affected by loss of sleep due to the sound of snoring."

Approximately 90 million Americans are suffering from either OSA or snoring. Provent, which is available only by prescription, has been validated in seven peer-reviewed clinical publications by renowned sleep experts providing consistent results in the treatment of all severities of OSA. This treatment is a simple, portable and less invasive alternative to CPAP machines for people with OSA.  Theravent, an over-the-counter product developed using similar technology as Provent, was rigorously tested in three clinical trials. The results, published in Sleep Diagnosis and Therapy, showed that it was effective in reducing and eliminating snoring.

"OSA and snoring are both global health issues in need of more effective treatment options," said Williams. "Provent and Theravent are easy to use, convenient and cost-effective for sufferers of such conditions, and are clinically proven to work."

Thousands of sleep physicians have recommended these therapies to treat patients with snoring or OSA. To learn more, visit and, or call 1-888-SLP-WELL (1-888-757-9355).

About Theravent, Inc.
Theravent, Inc. is a privately-held medical device company dedicated to providing noninvasive medical solutions for people with sleep disordered breathing. Based on its innovative MicroValve technology and patented designs, Theravent, Inc. has developed a unique line of clinically-proven medical devices to address the continuum of sleep disorders from severe obstructive sleep apnea (OSA) to mild snoring. Theravent, Inc.'s devices work by creating expiratory positive airway pressure (EPAP). The company markets prescription-only Provent Sleep Apnea Therapy, a discreet, easy-to-use nasal device for the treatment of OSA, and Theravent Snore Therapy, an over-the-counter device for the treatment of primary snoring, in the US. Provent is also available in Australia, New Zealand, Canada, Hong Kong, Singapore and South Africa. For more information, please visit or

SOURCE Theravent, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Specialty Pharmacy Association of America (SPAARx) - Enrollment Exceeds 1,000 Members in First Two Weeks since Launch
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Delcath Systems, Inc. Secures $20 Million Credit Facility
4. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
5. Arthrosurface Hits a $100 Million Milestone
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
8. Independa Closes Convertible Note Funding at $2.35 Million
9. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
10. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
11. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ) has ... Market Outlook to 2019 - Rise in Cardiac Disorders and ... report to their offering. Boston ... scientific and others. --> The ... Boston scientific and others. ...
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Japanese Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... convenient way to dispense prescription medications at home, so he invented the patent-pending ... monitor and dispense prescription medications. In doing so, it could help to prevent ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... online platform for mental health and wellness consultation, has collaborated with a leading ... bridge the knowledge gap experienced by parents and bring advice from parenting experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
Breaking Medicine News(10 mins):